Report of Independent Accountants

To the Board of Trustees and Management of John Hancock Funds II

We have examined management's assertion, included in the accompanying Management Statement Regarding Compliance with Certain Provisions of the Investment Company Act of 1940, that each series of John Hancock Funds II (as set forth in the attached Schedule of Portfolios) (hereafter individually referred to as the "Portfolio", collectively the "Portfolios") complied with the requirements of subsections (b) and

(c)of Rule 17f-2 under the Investment Company Act of 1940 ("the Act") as of August 31, 2022. The Portfolio's management is responsible for its assertion and each Portfolio's compliance with those requirements. Our responsibility is to express an opinion on management's assertion about each Portfolio's compliance with the specified requirements based on our examination.

Our examination was conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States) and in accordance with attestation standards established by the American Institute of Certified Public Accountants. Those standards require that we plan and perform the examination to obtain reasonable assurance about whether management's assertion about compliance with the specified requirements is fairly stated, in all material respects, and, accordingly, included examining, on a test basis, evidence about each Portfolio's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances. Included among our procedures were the following tests performed as of August 31, 2022, and with respect to agreement of security purchases and sales, for the period from April 31, 2022 (the date of our last examination), through August 31, 2022:

-Confirmation of securities (the number of shares of beneficial interest of the underlying funds) owned by each Portfolio and held by Variable Products and Annuities, a division of John Hancock Life Insurance Company, USA, a transfer agent that uses the book entry method of accounting for shares;

-Reconciliation of all such securities (shares of beneficial interest of the underlying funds) to the books and records of each Portfolio and John Hancock Life Insurance Company, USA; and,

-Agreement of a sample of purchases of shares of beneficial interest of the underlying funds and a sample of security sales of shares of beneficial interest of the underlying funds by each Portfolio as set forth in the attached Schedule of Portfolios since our last report from the books and records of each Portfolio to confirmations received from John Hancock Life Insurance Company, USA.

We believe that our examination provides, and that the evidence we obtained is sufficient and appropriate to provide, a reasonable basis for our opinion. Our examination does not provide a legal determination on each Portfolio's compliance with the specified requirements.

We are required to be independent and to meet our other ethical responsibilities in accordance with relevant ethical requirements related to the engagement.

In our opinion, management's assertion that each of the series of John Hancock Funds II (as set forth in the attached Schedule of Portfolios) complied with the requirements of subsections (b) and (c) of Rule 17f- 2 of the Investment Company Act of 1940 as of August 31, 2022 with respect to securities reflected in the investment account of the Company is fairly stated, in all material respects.

This report is intended solely for the information and use of management and the Board of Trustees of the Portfolios and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than the specified parties.

/s/ PricewaterhouseCoopers LLP Boston, Massachusetts October 4, 2022

PricewaterhouseCoopers LLP, 101 Seaport Boulevard, Suite 500, Boston, MA 02210

T: (617) 530 5000, F: (617) 530 5001, www.pwc.com/us